- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02801331
Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome
A Randomized Controlled Study of Stochastic Vibrotactile Stimulation for Neonatal Abstinence Syndrome: Therapeutic Efficacy and Neurobehavioral Outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will test the therapeutic efficacy of stochastic vibrotactile stimulation (SVS) for reducing withdrawal symptoms, pharmacological treatment and hospitalization, and for improving neurobehavioral developmental outcomes in opioid-exposed newborns.
Candidates at-risk for NAS due opioid exposure in utero will be identified to investigators by medical caregiver and/or prescreened using HIPAA Waiver for recruitment (maternal-prenatal; infant-postnatal). Infants will be randomized into either SVS (complementary to standard of care) or Treatment as Usual (TAU), restricted by equipment (mattress) availability. Infants will be enrolled and assigned to a condition within 48 hours post birth and participate throughout hospitalization. Infants assigned SVS will receive daily intervention of continuous intervals of SVS throughout hospitalization using a specially constructed crib mattress that delivers gentle vibrations at preset intervals.
Specific Aim 1. Determine the efficacy of SVS as a non-pharmacological therapy complementary to standard of care for reducing severity and duration of opioid withdrawal in newborns compared to TAU alone. Quantify clinical variables: NAS severity, treatment days, days in hospital, velocity of weight gain, cumulative morphine dose.
Specific Aim 2. Compare neurobehavioral outcomes in fetal drug-exposed infants between infants who received SVS and those who received TAU. Longitudinal outcomes assessment at 6-months and 1 year to test whether early intervention with SVS compared to standard care improves physical, social, emotional and cognitive development.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Eligible subjects are infants currently in the NICU or Newborn Nursery at University of Massachusetts Memorial Hospital or at Magee Women's Hospital of UPMC and:
- Full-term infants (≥37 wks gestational age)
- Newborns at risk for NAS due to opioid-exposure in utero
- At-risk infants will be infants who present with confirmed meconium and/or urine toxicology report and/or documented medical record for opioids (e.g., methadone, buprenorphine/subutex, oxycodone, heroin); may also have prenatal exposure to benzodiazepines, barbiturates, amphetamines, cannabinoids, alcohol, nicotine and/or caffeine.
Exclusion Criteria: Eligible infants meeting the inclusion criteria above will be excluded from participation in the study if he/she:
- Born less than <37weeks.
- Has a clinically significant congenital abnormality
- Has a clinically significant fetal anomaly
- Has hydrocephalus or intraventricular hemorrhage >grade 2
- Has a seizure disorder not related to drug withdrawal
- Has a clinically significant cardiac shunt
- Has anemia (hemoglobin<8g/dL)
- Requires mechanical respiratory support
- Has MRSA or infection at time of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stochastic Vibrotactile Stimulation (SVS)
Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth.
SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed).
Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
|
Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle vibrations and sounds during mattress stimulations.
|
No Intervention: Treatment as Usual (TAU)
Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed).
Infants will not receive any SVS.
Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacological Treatment-Dose
Time Frame: Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Cumulative morphine dose
|
Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Pharmacological Treatment-Duration
Time Frame: Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Total days of morphine treatment
|
Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Neurobehavioral Outcomes Assessment
Time Frame: Participants will be assessed at approx 1 month, 6 months, and 12 months
|
Neurobehavioral infant assessment at 6 month followup
|
Participants will be assessed at approx 1 month, 6 months, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Velocity of weight gain
Time Frame: Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Trajectory of weight gain throughout hospitalization-Days to return to birth weight
|
Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Hospitalization length of stay
Time Frame: Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Duration of infant hospitalization
|
Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory rate
Time Frame: Assess respiratory rate for about 12 consecutive hours at week 1 and week 2 of infant hospitalization
|
Respiratory rate at 1 and/or 2 weeks of age assessed for about 12 consecutive hours in a subset of hospitalized subjects
|
Assess respiratory rate for about 12 consecutive hours at week 1 and week 2 of infant hospitalization
|
Cardiac activity
Time Frame: Assess heart rate for about 12 consecutive hours at week 1 and week 2 of infant hospitalization
|
Heart rate at 1 and/or 2 weeks of age assessed for about 12 consecutive hours in a subset of hospitalized subjects
|
Assess heart rate for about 12 consecutive hours at week 1 and week 2 of infant hospitalization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elisabeth B Salisbury, Ph.D., University of Massachusetts, Worcester
Publications and helpful links
General Publications
- Pahl A, Young L, Buus-Frank ME, Marcellus L, Soll R. Non-pharmacological care for opioid withdrawal in newborns. Cochrane Database Syst Rev. 2020 Dec 21;12(12):CD013217. doi: 10.1002/14651858.CD013217.pub2.
- Bloch-Salisbury E, Bogen D, Vining M, Netherton D, Rodriguez N, Bruch T, Burns C, Erceg E, Glidden B, Ayturk D, Aurora S, Yanowitz T, Barton B, Beers S. Study design and rationale for a randomized controlled trial to assess effectiveness of stochastic vibrotactile mattress stimulation versus standard non-oscillating crib mattress for treating hospitalized opioid-exposed newborns. Contemp Clin Trials Commun. 2021 Feb 11;21:100737. doi: 10.1016/j.conctc.2021.100737. eCollection 2021 Mar.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY21040054
- 1R01DA042074-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Abstinence Syndrome
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Milton S. Hershey Medical CenterNational Institute on Drug Abuse (NIDA)RecruitingNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal SyndromeUnited States
-
Spark Biomedical, Inc.Medical University of South Carolina; University of Texas Southwestern Medical...RecruitingNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal SyndromeUnited States
-
Thomas Jefferson UniversityChiesi Farmaceutici S.p.A.CompletedNeonatal Abstinence Syndrome | Neonatal Opiate Withdrawal SyndromeUnited States
-
PediatrixCompletedNeonatal Abstinence Syndrome | Neonatal Withdrawal SyndromeUnited States
-
Tufts Medical CenterCompletedNeonatal Abstinence Syndrome | Neonatal Opioid WithdrawalUnited States
-
Tulane UniversityRecruitingNeonatal Abstinence Syndrome | Substance Withdrawal, NeonatalUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompletedOpioid-use Disorder | Neonatal Abstinence Syndrome | Opioid Withdrawal | Neonatal Opioid Withdrawal SyndromeUnited States
-
University of AlbertaAlberta Health services; Alberta Innovates Health Solutions; Covenant HealthRecruitingNeonatal Abstinence SyndromeCanada
-
University Hospital, CaenRecruitingNeonatal Abstinence SyndromeFrance
Clinical Trials on Stochastic Vibrotactile Stimulation (SVS)
-
University of Massachusetts, WorcesterCompletedNeonatal Abstinence SyndromeUnited States
-
University of ArizonaVirginia Polytechnic Institute and State UniversityNot yet recruiting
-
Donders Centre for Cognitive NeuroimagingParkinson's FoundationCompleted
-
University of DelawareRecruiting
-
University of Colorado, DenverRecruiting
-
Marquette UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingStroke | Proprioceptive DisordersUnited States
-
Stanford UniversityJohn A Blume FoundationCompleted
-
Stanford UniversitySuspendedLow Back Pain | Chronic Pain | Migraine | Pelvic Pain | Functional Abdominal Pain SyndromeUnited States
-
National Yang Ming UniversityTaipei Veterans General Hospital, TaiwanUnknownHealthy | Stroke, IschemicTaiwan
-
University of MinnesotaRecruiting